T helper cells provide molecular signals to antigen-presenting cells (APCs) that have captured antigens. These signals, together with recognition of pathogen- or danger-associated molecular patterns, effectively licence APC to drive proliferation and differentiation of effector T cells. This helper role can also be performed by type I NKT cells, an unconventional T cell population with restricted TCR usage that respond to a limited range of glycolipid antigens. Because NKT cells are abundant, and exhibit a semi-activated phenotype, this source of help is rapid and effective, and can licence APC in the absence of pattern-recognition. Glycolipid antigens that function as agonists for NKT cells have therefore been explored as immune adjuvants. Here I describe work on this concept, ultimately focussing on novel vaccine platforms to enhance codelivery of antigen and agonist to APC to facilitate T cell responses. A notable feature of this vaccine platform is the capacity to induce accumulation of resident-memory CD8+ T cells in the liver, a promising strategy for eliciting responses against liver infections.